At a glance overview of the worldwide impact of depression, focusing on various aspects such as its prevalence, economic burden, treatment challenges, and emerging research areas.
The infographic shows a 27% increase in depression cases due to COVID-19, affecting 280 million people worldwide. The economic impact in the U.S. reached $326 billion in 2018, a 35% increase since 2010. About 30% of those with Major Depressive Disorder (MDD) are resistant to standard treatments. There’s growing interest in psychedelic research for treating depression, focusing on their ability to activate brain receptors and promote neuroplasticity.
Related content
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition with significant individual and socio-economic burden. Despite the broad availability of numerous effective therapeutic interventions, up to 30% of patients fail to achieve adequate symptom relief and are classified as having treatment-resistant depression (TRD). TRD represents a significant clinical challenge, affecting approximately 30% of individuals with MDD who fail to respond to at least two adequate antidepressant trials.
Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.
Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.